YMAB - Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance M.D. as Chief Development Officer | Benzinga
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.
"We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in developing Targeted Radiotherapies and radiopharmaceuticals, Norman will play a key role in the further advancement of our novel Self-Assembly DisAssembly Pretargeted Radioimmunotherapy ("SADA-PRIT") technology platform in support of our mission to improve the lives of patients with cancer and other serious diseases."
Dr. LaFrance brings over 40 years of deep radiopharmaceutical experience as both a nuclear medicine physician and pharmaceutical executive. He previously served as the Chief Medical Officer, Senior Vice President of PLUS Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company where he led the development of targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Before Plus Therapeutics, Dr. LaFrance served as Chief Medical Officer at Jubilant Pharma Ltd., where he was responsible for all Pharmaceutical & Medical Regulatory Affairs activities. Prior to Jubilant, Dr. LaFrance served as Global Chief Medical Officer at IBA Molecular and earlier, as Senior Vice President and Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc.
Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of Medicine and Radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the U.S. along with active, professional society membership. Dr. LaFrance received his B.S and Master of Engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his M.D. from the University of Arizona, College of Medicine, Tucson.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company ...